Medicina (Sep 2021)

Diagnosing a Patient with Erdheim-Chester Disease during the COVID-19 Pandemic

  • Georgia Kaiafa,
  • Dimitrios Pilalas,
  • Triantafyllia Koletsa,
  • Stylianos Daios,
  • Georgios Arsos,
  • Adam Hatzidakis,
  • Adonis Protopapas,
  • Kostas Stamatopoulos,
  • Christos Savopoulos

DOI
https://doi.org/10.3390/medicina57101001
Journal volume & issue
Vol. 57, no. 10
p. 1001

Abstract

Read online

Background: Erdheim-Chester disease (ECD) is a rare hematopoietic neoplasm of histiocytic origin characterized by an insidious course. The coronavirus disease 2019 (COVID-19) pandemic has put an enormous strain on healthcare systems worldwide both directly and indirectly, resulting in the disruption of healthcare services to prevent, diagnose and manage non-COVID-19 disease. Case Presentation: We describe the case of a 58-year-old male patient with sporadic episodes of self-resolving mild fever and anemia of chronic disease with onset two years before the current presentation. Positron emission/computed tomography scan revealed the presence of moderately hypermetabolic perirenal tissue masses. In order to achieve diagnosis, repeated perirenal tissue biopsies were performed, and the diagnostic evaluation was complicated by the strain put on the healthcare system by the COVID-19 pandemic. The patient contracted SARS-CoV-2 and required hospitalization, but recovered fully. No further ECD target organ involvement was documented. Treatment options were presented, but the patient chose to defer treatment for ECD. Conclusion: A high index of suspicion and multidisciplinary team collaboration is paramount to achieve diagnosis in rare conditions such as ECD. Disruptions in healthcare services in the pandemic milieu may disproportionately affect people with rare diseases and further study and effort is required to better meet their needs in the pandemic setting.

Keywords